1. Home
  2. FRBA vs EOLS Comparison

FRBA vs EOLS Comparison

Compare FRBA & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FRBA

First Bank

HOLD

Current Price

$17.26

Market Cap

414.6M

Sector

Finance

ML Signal

HOLD

Logo Evolus Inc.

EOLS

Evolus Inc.

HOLD

Current Price

$6.85

Market Cap

454.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRBA
EOLS
Founded
2007
2012
Country
United States
United States
Employees
336
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
414.6M
454.4M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
FRBA
EOLS
Price
$17.26
$6.85
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$17.50
$15.50
AVG Volume (30 Days)
114.2K
758.9K
Earning Date
04-27-2026
05-04-2026
Dividend Yield
2.40%
N/A
EPS Growth
N/A
1.23
EPS
N/A
N/A
Revenue
N/A
$297,176,000.00
Revenue This Year
$14.68
$13.27
Revenue Next Year
$6.08
$17.62
P/E Ratio
$9.71
N/A
Revenue Growth
N/A
11.61
52 Week Low
$14.41
$3.86
52 Week High
$18.19
$10.20

Technical Indicators

Market Signals
Indicator
FRBA
EOLS
Relative Strength Index (RSI) 57.67 53.68
Support Level $14.71 $6.44
Resistance Level $17.46 $6.95
Average True Range (ATR) 0.46 0.31
MACD -0.02 -0.04
Stochastic Oscillator 51.85 46.67

Price Performance

Historical Comparison
FRBA
EOLS

About FRBA First Bank

First Bank is a full-service commercial bank, with target businesses from individuals, businesses, and governmental entities located in service regions throughout New Jersey and eastern Pennsylvania, with a particular focus between New York City and Philadelphia. The group focuses on traditional deposit and loan products with businesses and individuals living and working in markets as the source of business. Its services are Business Banking, Personal Banking, Digital Banking, and Lending.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.

Share on Social Networks: